📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Peer Medians

About

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding TFX

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Seth Klarman Baupost Group	1.60M	$190.8M	3.73%	Mar 2026
Steve Cohen Point72 Asset Management	677.3K	$81.0M	0.10%	Mar 2026
Jim Simons Renaissance Technologies LLC	56.7K	$6.8M	0.01%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management used phrases like 'continued progress', 'exceeded the high end of our previous guidance', and provided specific numbers for revenue beat and EPS increase. The tone was assured and data-backed throughout.

Q3 2025

Confident Specific

Management used positive language about execution and strategic progress ('pleased with our execution', 'significant progress in executing our strategy'), while openly acknowledging headwinds and providing specific adjustments to intra-aortic balloon pump and tariff expectations. The tone is direct and data-driven.

Q4 2025

Confident Specific

Management provided precise guidance ranges (revenue 4.5-5.5% constant currency growth, EPS $6.25-$6.55) and quantified stranded costs ($90M) and restructuring savings ($50M), while acknowledging near-term headwinds and tariff uncertainty.

Q1 2026 latest

Confident Specific

Management repeatedly used phrases like 'pleased with the performance', 'exceeded our internal expectations', and 'we expect' while providing specific numbers (5.1% pro forma growth, 18.1% operating margin). However, they acknowledged specific headwinds (tariffs, supplier recall, integration disruption) without downplaying their materiality.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis remains intact but with near-term noise. Management demonstrated execution with a Q1 beat, but acknowledged transitory headwinds (integration disruption, supplier recall, tariffs) that could temporarily mute margin and growth. The transformation (divestitures, buyback, debt reduction) is on track and expected to significantly improve 2027 financials. Key watches: timing of divestiture closures, resolution of tariff refunds, and whether the supplier recall becomes material. The new CEO's strategic vision will be critical. Overall thesis appears unchanged, with confidence in long-term value creation reinforced by capital allocation discipline.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Teleflex Q1 2026 revenue $548.3M, pro forma constant currency growth 5.1%

Revenue & Profitability

First quarter 2026 GAAP revenue was $548.3 million, up 32.3% year-over-year. Pro forma adjusted constant currency revenue growth was 5.1%. Adjusted earnings per share was $1.39, a decrease of 3.5% year-over-year. Adjusted gross margin was 61.4%, down 470 basis points, and adjusted operating margin was 18.1%, down 510 basis points. Adjusted net interest expense totaled $24 million, and cash equivalents were $329.6 million at quarter end.

Outlook

Management reiterated 2026 full-year guidance for pro forma adjusted constant currency revenue growth of 4.5% to 5.5% and adjusted EPS of $6.25 to $6.55. They expect accelerated growth in the second half of 2026, particularly in the interventional segment, following the integration of sales forces. The company anticipates 2027 will be a more reflective year of the underlying business, with significant improvements in margins and EPS driven by the completion of strategic divestitures, share repurchases, and debt reduction.

Growth Drivers

Key growth drivers include strong performance in the vascular segment (hemostatic products and central venous access portfolios), interventional segment (intraosseous, right heart catheters, complex catheters), and surgical segment (ligation clips and bariatric stapler). The company is investing heavily in R&D (~8% of sales) and expanding the Freesolve scaffold into additional geographies. The combination of the legacy Teleflex interventional and Vascular Intervention sales forces is expected to drive cross-selling in the cath lab.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Adjusted gross margin in Q1 2026 was 61.4%, down 470 basis points from the prior year, primarily due to tariffs, quality remediation charges, and the addition of the lower-margin Vascular Intervention business. Adjusted operating margin was 18.1%, down 510 basis points. The company expects full-year 2026 adjusted operating margin to be approximately 19%, including about $90 million in stranded costs. Management estimates an underlying steady-state adjusted operating margin of approximately 23% once transition service agreements are in place.

Key Risks

Risks highlighted include disruption from sales force integration and restructuring in the interventional segment, a third-party supplier recall affecting certain vascular interventional kits, and the impact of tariffs (estimated at $33 million for full year 2026). The company also noted lumpiness in surgical instrument orders and the receipt of a second request from the FTC for the acute care and interventional urology divestitures. Foreign exchange is expected to impact revenue by approximately $14 million in 2026.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Q2 2026 saw strong Vascular and Surgical growth, offset by Interventional integration delays, leading to lowered revenue guidance but higher adjusted EPS outlook. Strategic divestitures and capital returns are progressing, with innovation milestones in EZPLAZ and Freesolve supporting future growth.

Q1 2026 Q1 2026 2026-05-07

Q1 2026 saw 32.3% revenue growth (GAAP) and 5.1% pro forma adjusted growth, with adjusted EPS down 3.5% year-over-year. Strategic divestitures and restructuring are on track, with significant margin and EPS improvements expected in 2027.

Q4 2025 Q4 2025 2026-02-26

Year-end results show 8.7% EPS growth and strong segment performance, with 2026 guidance reflecting a transition year due to divestitures and stranded costs. Significant EPS and margin improvements are expected in 2027 as cost offsets, share repurchases, and debt reduction take effect.

Q3 2025 Q3 2025 2025-11-06

Separation into RemainCo and NewCo is progressing, with a sale of NewCo prioritized due to strong buyer interest. Q3 revenue grew 19.4% year-over-year, with adjusted EPS up 5.2%. Guidance for 2025 was updated, reflecting lower balloon pump demand and improved tariff outlook.

Q2 2025 Q2 2025 2025-07-31

Second quarter revenue and EPS exceeded guidance, driven by strong Interventional growth and operational execution. The BIOTRONIK Vascular Intervention acquisition boosts 2025 revenue and margin outlook, while tariff mitigation and CMS reimbursement proposals support future performance.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.